affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →
Editor, vendor desk
Mara leads the vendor-audit desk at vialaudit. Before this she spent a decade covering pharmaceutical-supply transparency for trade publications, and a stint as an analyst at a generics-compounding firm — which is where she learned how COA practices vary in the wild and why most vendor reviews online aren't worth the bytes they're written in. Mara handles the vendor relationships, the audit-cycle calendar, the methodology page, and the corrections feed. She does not accept retainers, sponsored content, or paid feature placements. Vendors do not get to review their audits before publication. That's the job. She writes under a pen name. The grey-market context makes real-name bylines impractical for the writers and risky for the labs. The tradeoff is real and we'd rather work pseudonymously than not at all.
Vendor audits, vendor postmortems, regulatory enforcement (503A, FDA, EMA), comparison pieces, and the audit-cycle calendar.
Five 503A telehealth compounders audited under the same rubric - Trillium, Fifty410, Hims, Henry Meds, Mochi Health. Mochi leads on prescriber transparency (board-certified obesity-medicine physicians). Fifty410 leads on regulatory cleanliness. The full cohort comparison, scored.
They're not really "versus" - the two compounds work through different receptors and synergize. CJC-1295 hits the GHRH receptor; ipamorelin hits the ghrelin receptor. The stack is research-protocol canon. Here's the actual breakdown plus the comparison framing most buyers want.
Two repurposed drugs studied for longevity, two different mechanisms, two different evidence bases. Rapamycin has the strongest cross-species lifespan-extension data in pharmacology. Metformin has 60+ years of human safety data and the active TAME trial. The honest comparison.
Both are synthetic GHRH analogs that stimulate endogenous growth hormone release. Tesamorelin is FDA-approved for HIV-associated lipodystrophy; sermorelin was approved for pediatric GH deficiency but withdrawn in 2008. Different half-lives, different research-protocol applications, different price points.
Tirzepatide produced ~47% greater mean weight loss than semaglutide in SURMOUNT-5, the first head-to-head obesity trial. Tirzepatide is dual GLP-1 / GIP, semaglutide is GLP-1-only. Both FDA-approved, both shifting the compounded-pharmacy market through 2026.
Bacteriostatic water tightened in 2025-2026 as compounded GLP-1 demand reshaped the diluent market. Here's the current vendor map, supply signals, and the alternatives that are research-protocol valid.
GLP-1 receptor agonists cause weight loss that is between 25% and 40% lean mass by default. Resistance training and protein intake shift that ratio. Here's the trial data and the protocol levers that actually move it.
The same operation now runs under two domains. The legacy site is still live, the new domain inherits the old contact infrastructure, and the Trustpilot review base was seeded via a promo-code review program. Here's the buyer-relevant breakdown.
We applied a 10-signal hostname-aliasing check to 32 research-peptide vendor domains. Multiple confirmed alias clusters surfaced, including a smoking-gun shared Google Tag Manager ID linking three "different" peptide brands to one operator.
We documented Particle Peptides selling Retatrutide as 'GLP-3' and Summit Biotech selling 8 different FDA-cited compounds under code names like 'R-10mg', 'T-30mg', 'Sema-1', and 'Cagri'. Here's the pattern, the evidence, and what buyers should do about it.
Some research-peptide brands aren't separate vendors — they're hostname aliases pointing at a shared backend. Here's how to detect the pattern in under sixty seconds, with a worked example from our own audit cohort.
When two 'different' peptide vendors cite the exact same Janoshik test URL for the same product batch, they're sourcing from the same upstream manufacturer. We documented this pattern between Summit Biotech and the Peptopia community-tracker batches — confirming Geneza Pharmaceuticals as the shared upstream.
Four structural drivers behind peptide-vendor alias clusters — payment-processor mortality, FDA enforcement, community detection lag, and upstream-supply-chain consolidation.
The compounded semaglutide market that emerged during the 2022–2024 brand-product shortage is largely closed in 2026. Here's what the FDA shortage status, 503A PCAC restrictions, and telehealth provider pivots actually mean for buyers.
The 2024 and 2026 Pharmacy Compounding Advisory Committee votes didn't close any peptide vendor — they closed the legal compounded GLP-1 telehealth channel (Hims, Ro, Mochi, Henry, Eden). That closure is what pushed demand toward the research-peptide market.
A timeline of FDA actions affecting the US research-peptide market from late 2024 through April 2026 — Warning Letters, criminal cases, and the 503A PCAC vote that reshaped what compounding pharmacies could legally produce.
Eight failure modes, ranked by how often they appear in public Janoshik data and how hard they are for a buyer to catch before ordering.
Amino Asylum, Peptide Sciences, and Paradigm Peptides each ceased operations under different circumstances. The signals that preceded each shutdown were public, dated, and ignored.
Retatrutide showed ~24% mean body-weight reduction in TRIUMPH-4 versus tirzepatide's ~22.5% in SURMOUNT — a 1.5–2 point delta. Retatrutide hits three receptors (GLP-1, GIP, glucagon), tirzepatide two. May 2026: retatrutide is Phase 3, not FDA-approved; tirzepatide is FDA-approved with compounded availability closing.
Live vendor pricing for retatrutide, COA verification steps, and the regulatory framing every buyer should read before ordering. Auto-refreshed daily from each vendor's catalog.
Tips, corrections, or comments on vendor desk coverage: vendors@vialaudit.com